Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone m...
Proteonomix reported revenue of $26,004 for fiscal year 2011, down 68.8% from fiscal year 2010, and net income of -$1.38 million. In Q2 2012 (the quarter ended June 30, 2012) revenue was $0.
Figures from company filings; latest fiscal year ended December 31, 2011.
No profile data available.